| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
866.07(B) |
| Last
Volume: |
3,374,911 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,771,329 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
50 |
93 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2016-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,556 |
120,546 |
|
- |
|
| Lechleiter John C |
Director |
– • – |
2016-08-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
650 |
717,244 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2016-08-15 |
4/A |
B |
$80.42 |
$205,875 |
D/D |
2,560 |
45,323 |
2.39 |
- |
|
| Tai Jackson P |
Director |
– • – |
2016-08-12 |
4/A |
B |
$80.00 |
$36,560 |
D/D |
457 |
42,763 |
2.39 |
- |
|
| Tai Jackson P |
Director |
– • – |
2016-08-12 |
4 |
B |
$80.42 |
$205,875 |
D/D |
2,560 |
42,110 |
2.39 |
- |
|
| Lechleiter John C |
Director |
– • – |
2016-08-11 |
5 |
GD |
$0.00 |
$0 |
D/D |
18,060 |
717,894 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2016-08-11 |
4/A |
B |
$80.52 |
$221,913 |
D/D |
2,756 |
42,306 |
2.39 |
- |
|
| Walsh Fionnuala M |
SVP, Global Quality |
• – – |
2016-08-03 |
4 |
D |
$83.32 |
$293,870 |
D/D |
(3,527) |
58,618 |
|
- |
|
| Walsh Fionnuala M |
SVP, Global Quality |
• – – |
2016-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
62,145 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-07-29 |
4 |
S |
$82.94 |
$17,001,880 |
D/D |
(205,000) |
125,775,804 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2016-07-29 |
4 |
A |
$79.95 |
$6,556 |
D/D |
82 |
47,081 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2016-07-29 |
4 |
A |
$79.95 |
$9,914 |
D/D |
124 |
31,902 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-07-28 |
4 |
S |
$82.82 |
$19,888,568 |
D/D |
(240,000) |
125,980,804 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2016-07-28 |
4 |
S |
$83.16 |
$100,873 |
D/D |
(1,213) |
1,300 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-07-12 |
4 |
S |
$79.54 |
$16,703,820 |
D/D |
(210,000) |
126,220,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-07-07 |
4 |
S |
$79.11 |
$17,806,358 |
D/D |
(225,000) |
126,430,804 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-06-30 |
4 |
S |
$78.14 |
$16,869,942 |
D/D |
(215,000) |
126,655,804 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2016-06-30 |
4 |
A |
$73.28 |
$6,595 |
D/D |
90 |
46,999 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2016-06-30 |
4 |
A |
$73.28 |
$9,893 |
D/D |
135 |
31,778 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-06-29 |
4 |
S |
$77.70 |
$17,129,163 |
D/D |
(220,000) |
126,870,804 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2016-06-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,541 |
8,169 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2016-06-10 |
4 |
S |
$73.77 |
$73,180 |
D/D |
(992) |
10,710 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2016-05-31 |
4 |
S |
$75.12 |
$15,023,200 |
D/D |
(200,000) |
127,090,804 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2016-05-31 |
4 |
A |
$78.29 |
$6,576 |
D/D |
84 |
46,592 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2016-05-31 |
4 |
A |
$78.29 |
$9,943 |
D/D |
127 |
31,425 |
|
- |
|
1436 Records found
|
|
Page 45 of 58 |
|
|
3.66 (0.4%) 
